Revance Therapeutics, Inc. $287.5 Million Convertible Senior Notes Offering

Davis Polk advised the initial purchasers in connection with a Rule 144A offering by Revance Therapeutics, Inc. of $287.5 million aggregate principal amount of its 1.75% convertible senior notes due 2027, including $37.5 million aggregate principal amount of convertible senior notes pursuant to the exercise of the initial purchasers’ option to purchase additional securities. In addition, Davis Polk advised counterparties to capped call transactions in connection with the offering.

Based in Newark, California, Revance Therapeutics is a specialty biopharmaceutical company developing neuromodulators for use in aesthetic and therapeutic indications.

The Davis Polk corporate team included partners Alan F. Denenberg and Emily Roberts and associates Beth LeBow and Kimberly Wang. The equity derivatives team included partner John M. Brandow, counsel Justin Michael and associate Joseph Luizzi. The tax team included partner Lucy W. Farr and associate Adam R. Brownstone. Partner Pritesh P. Shah provided intellectual property and technology advice. Members of the Davis Polk team are based in the Northern California and New York offices.